- Ariad Pharmaceuticals (NASDAQ:ARIA -0.3%) Q4 results: Revenues: $66.8M (+695.2%); COGS: $0.9M (-89.7%); R&D Expense: $32.6M (-8.9%); SG&A: $40.4M (+7.4%); Net Loss: ($5.8M) (+92.2%); Loss Per Share: ($0.03) (+92.5%).
- FY2014 results: Revenues: $105.4M (+131.1%); COGS: $5.2M (-45.8%); R&D Expense: $120.6M (-26.0%); SG&A: $139.8M (-4.6%); Net Loss: ($162.6M) (+40.7%); Loss Per Share: ($0.87) (-41.6%); Quick Assets: $352.7M (48.7%); CF Ops: ($57.8M) (+74.0%).
- 2015 Guidance: Iclusig Net Product Revenue: $130M - 140M; R&D: $185M - 195M; SG&A: $135M - 145M; Cash and Cash Equivalents : atleast $200M.